New Insights About Doxorubicin-Induced Toxicity to Cardiomyoblast-Derived H9C2 Cells and Dexrazoxane Cytoprotective Effect: Contribution of In Vitro1H-NMR Metabonomics
Doxorubicin (DOX) is an anticancer drug widely used in oncology.The main limitation to DOX treatments though is due to the cumulative dose that may lead to cardiotoxicity.Clinically, DOX-induced cardiomyopathy develops as a progressive heart failure consecutive to a progressive loss in cardiomyocytes due to cell necrosis and apoptosis induced by DO